The Senate Special Committee on Aging conducted a hearing last week to try to develop a strategy to reform the Medicare program in a way that would be acceptable to both Democrats and Republicans.
Ranking Member Bob Corker (R-TN) called for the hearing, A Time for Solutions: Finding Consensus in the Medicare Reform Debate, to develop specific recommendations that could be passed on to the Joint Select Committee on Deficit Reduction. Citing Congressional Budget Office (CBO) baseline estimates that Medicare spending will increase 56 percent to one trillion dollars in the next ten years, Senator Corker emphasized the need for reform. “Medicare is America’s largest fiscal and health care challenge and is getting more difficult to solve every day we don’t address it,” said Senator Corker.
Panelists agreed that Medicare reform is needed. Although they differed on emphasis, there were commonalities in many panelists’ approaches to reform. Panelists, for example, agreed on raising the eligibility age. Some cited a gradual increase to age 67, while others avoided naming a specific number. Panelists also agreed on restructuring incentives to encourage both providers and beneficiaries to cut costs. In order to do this many of the panelists advocated for increased cost sharing. “Medicare is a hodge-podge of various different deductibles, co-pays, and co-insurance rates that are too complex and confusing to establish the correct incentives,” said Maya MacGuineas, President of the Committee for a Responsible Federal Budget. “On top of that, many seniors purchase Medigap or other supplemental insurance to cover most or all of their cost-sharing – meaning that for many beneficiaries there is no real ‘skin in the game.’”
In addition to the panelists’ testimony, Chairman of the Senate Special Committee on Aging, Herb Kohl (D-WI,) released a letter he sent to the Co-Chairs of the Joint Select Committee on Deficit Reduction. The letter outlined Senator Kohl’s own recommendations for reforming Medicare and other programs that affect seniors. His recommendations include allowing Medicare to negotiate drug prices in Medicare Part B when it is the majority purchaser, reducing the incentive for doctors to prescribe name brand drugs over generics, and requiring drug manufacturers to discount medication for low-income Medicare beneficiaries.
Read the panelists’ statements and view the hearing in its entirety.
Federal Agency Activity, Health and Wellness, Quality of Life
The National Quality Forum is embarking on a new two-year project to create a framework for quality measurement for residents living in a community wh...
The Administration for Community Living is reorganizing, including expanding the Office of Elder Rights to become the Office of Elder Justice and Adul...
cheatsheet, Clinical Quality and Quality Care Delivery, Federal Agency Activity, Health and Wellness, Managed Risk
The Centers for Disease Control and Prevention has issued infection prevention and control recommendations for hospitalized patients with known or sus...
Federal Agency Activity, Medicaid, Medicare
The White House has unveiled the website for the 2015 White House Conference on Aging. The site whitehouseconferenceonaging.gov includes information o...
Advocacy, Affiliate and Chapter Events, Affiliate/Chapter, Business Planning, CEO, cheatsheet, Engage, Policy in the States
Florida ALFA has been poised for progress since its establishment in July 2012. The state is a haven for retirees who are attracted by the climate, cl...
Federal Agency Activity, Health and Wellness, Memory Care Best Practices and Research, Memory Care Education
The National Institutes of Health announced a set of investments totaling $46 million to support the goals of the BRAIN initiative, a large-scale effo...
Federal Agency Activity, Medication Management
Long-term care communities now will be able to better assist in the disposal of prescription drugs belonging to current or former residents with the a...
End of Life, Federal Agency Activity, Health and Wellness, Managed Risk, Memory Care Best Practices and Research
The Food and Drug Administration has announced it plans to take concerted efforts to improve the collection and availability of clinical trial data on...
ALFA's Public Policy Positions, Engage, Policy in the States
A top ALFA priority is to monitor legislative and regulatory activity throughout the states. By keeping a close watch on state activity, ALFA is able ...